Cargando…
Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
Autores principales: | Pires, Eusebio S., D'Souza, Ryan S., Needham, Marisa A., Herr, Austin K., Jazaeri, Amir A., Li, Hui, Stoler, Mark H., Anderson-Knapp, Kiley L., Thomas, Theodore, Mandal, Arabinda, Gougeon, Alain, Flickinger, Charles J., Bruns, David E., Pollok, Brian A., Herr, John C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362548/ https://www.ncbi.nlm.nih.gov/pubmed/28403580 http://dx.doi.org/10.18632/oncotarget.15755 |
Ejemplares similares
-
Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
por: Pires, Eusebio S., et al.
Publicado: (2015) -
Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer
por: Knapp, Kiley A., et al.
Publicado: (2018) -
Ovastacin cuts off sperm binding
por: Short, Ben
Publicado: (2012) -
Ovastacin: An oolemma protein that cleaves the zona pellucida to prevent polyspermy
por: Kang, Inyoung, et al.
Publicado: (2023) -
Mammalian plasma fetuin-B is a selective inhibitor of ovastacin and meprin metalloproteinases
por: Karmilin, Konstantin, et al.
Publicado: (2019)